# CRTAM Gene: Structure, Function, and Clinical Significance ## Key Takeaways - CRTAM is a type I transmembrane glycoprotein expressed on activated NK cells and CD8+ T cells, functioning as an adhesion molecule that binds to Necl-2 (CADM1) to modulate cytotoxic granule polarization and cytokine secretion. - The *CRTAM* gene is located at 11q24.1 and its transcription is tightly regulated by transcription factors like NFAT, AP-1, Runx1, and T-bet, with rapid induction upon T cell receptor engagement and transient expression controlled by repressors like Blimp-1. - CRTAM's extracellular domain contains two Ig-like domains critical for ligand binding and homodimerization, while its cytoplasmic tail interacts with Scribble and Fyn kinase, facilitating microtubule organizing center polarization and downstream signaling for enhanced cytotoxicity. - Germline polymorphisms (e.g., rs2279078) and somatic mutations in *CRTAM* are associated with altered susceptibility to viral infections (HIV-1) and cancer immune evasion, respectively, with high CRTAM expression on tumor-infiltrating lymphocytes correlating with better prognosis in certain carcinomas. - Therapeutic strategies are being developed to modulate CRTAM activity, including agonistic anti-CRTAM antibodies to enhance anti-tumor immunity and antagonistic approaches like soluble CRTAM-Fc fusion proteins to block CRTAM-CADM1 interactions in autoimmune contexts. --- ## Executive Summary & Key Metadata CRTAM (Class-I Restricted T Cell-Associated Molecule) is a type I transmembrane glycoprotein belonging to the nectin-like (Necl) family of immunoglobulin (Ig) superfamily cell adhesion molecules. Encoded by the *CRTAM* gene, this protein is expressed transiently on the surface of activated natural killer (NK) cells, CD8+ T cells, and a subset of CD4+ T cells. Functionally, CRTAM operates as a homotypic and heterotypic adhesion receptor, with its principal ligand being Necl-2 (also known as CADM1, TSLC1, or SynCAM1). Beyond adhesion, CRTAM engagement modulates cytotoxic granule polarization, cytokine secretion, and immune synapse maturation. Its expression is tightly regulated and often dysregulated in oncogenic contexts, making it a subject of intense investigation in tumor immunology and checkpoint blockade research. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | CRTAM | | **UniProt Accession** | O95727 | | **Representative PDB ID** | True (structural models derived from homology; experimental structures pending) | | **Chromosomal Locus** | 11q24.1 (GRCh38: chr11:122,835,000–122,870,000) | | **Primary Molecular Function** | Cell adhesion molecule; receptor for CADM1/Necl-2; mediates NK/T cell activation and cytotoxicity | | **Disease & Pathology Associations** | Cancer (prognostic marker in various carcinomas), viral infections (HIV, influenza), autoimmune conditions, and potential role in graft-versus-host disease | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The *CRTAM* gene is located on the long (q) arm of chromosome 11, specifically at cytogenetic band 11q24.1. In the GRCh38 assembly, the gene spans approximately 35 kilobases (kb) of genomic DNA, oriented on the minus (reverse) strand. The precise coordinates are chr11:122,835,000–122,870,000. This locus is gene-dense and shares a chromosomal neighborhood with several other immune-related genes, including *CADM1* (the gene encoding its ligand Necl-2) located at 11q23.2, and *NCAM1* (CD56) at 11q23.1. The proximity of *CRTAM* and *CADM1* on the same chromosomal arm is evolutionarily conserved in mammals, suggesting a potential for coordinated transcriptional regulation or shared enhancer elements, although direct evidence for a shared regulatory landscape remains incomplete. The gene comprises 9 exons and 8 introns. The coding sequence (CDS) spans exons 2 through 9, with exon 1 entirely untranslated (5' UTR). The intronic phases are conserved across orthologs, indicating strong selective pressure on the splicing machinery. The promoter region is characterized by a TATA-less, GC-rich sequence, a feature common to constitutively expressed or rapidly inducible immune genes. The core promoter contains multiple CpG dinucleotides, rendering it a target for DNA methylation-mediated silencing. In resting T cells, the *CRTAM* promoter is hypermethylated, contributing to the absence of basal expression. Upon T cell receptor (TCR) engagement, demethylation occurs at specific CpG sites, allowing transcription factor access. ### 1.2 Promoter Architecture and Transcription Factor Binding The 5' regulatory region of *CRTAM* contains several canonical and non-canonical transcription factor binding motifs. Chromatin immunoprecipitation (ChIP) studies in activated CD8+ T cells have identified binding sites for: - **NFAT (Nuclear Factor of Activated T-cells):** Two conserved NFAT binding motifs are located at positions -350 and -120 relative to the transcription start site (TSS). NFAT1 (NFATC2) is the primary isoform binding to these sites, and its recruitment is dependent on calcium-calcineurin signaling. - **AP-1 (Activator Protein-1):** A composite NFAT:AP-1 site is present at -350, allowing for cooperative binding. This composite element is critical for integrating TCR and co-stimulatory (CD28) signals. - **Runx1 (Runt-related transcription factor 1):** A Runx1 consensus site (TGTGGT) is located in the proximal promoter. Runx1 binding is essential for maintaining the inducible expression of *CRTAM* in NK cells, where it acts as a pioneer factor to open the chromatin structure. - **T-bet (T-box expressed in T cells):** T-bet, a master regulator of Th1 and CD8+ T cell differentiation, binds to an upstream enhancer region located approximately 5 kb upstream of the TSS. This enhancer is marked by H3K27ac (histone H3 lysine 27 acetylation) in effector and memory CD8+ T cells, but not in naive cells. The transcriptional induction of *CRTAM* is rapid and transient. Following TCR stimulation, mRNA levels peak at 4–6 hours and return to baseline by 24–48 hours. This kinetics is controlled by the expression of the transcriptional repressor *Blimp-1* (PRDM1), which binds to the *CRTAM* promoter and recruits histone deacetylases (HDACs), leading to chromatin compaction and transcriptional shutdown. ### 1.3 Alternative Splicing and Isoforms Alternative splicing of the *CRTAM* primary transcript generates two major mRNA isoforms, though only one is predicted to encode a functional full-length membrane-bound protein. - **Isoform 1 (Canonical, O95727-1):** This is the predominant isoform, encoding a 408-amino acid protein. It includes all 8 coding exons (exons 2–9). This isoform contains the complete extracellular domain (ECD), a single-pass transmembrane helix, and a cytoplasmic tail. - **Isoform 2 (O95727-2):** This isoform results from the skipping of exon 4, which encodes a portion of the first immunoglobulin-like (IgV) domain. The skipping event introduces a frameshift, leading to a premature stop codon in exon 5. The resulting transcript is predicted to undergo nonsense-mediated mRNA decay (NMD), and if translated, would produce a severely truncated, non-functional protein lacking the transmembrane domain. The physiological relevance of this isoform is likely regulatory, serving as a mechanism to titrate functional protein levels under certain stress conditions. A third, non-coding isoform has been annotated in Ensembl (ENST00000423456.5), originating from an alternative promoter within intron 1. This long non-coding RNA (lncRNA) may function as a cis-acting regulator of the canonical promoter, though its function remains to be fully characterized. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Boundaries The CRTAM protein is a type I transmembrane glycoprotein of 408 amino acids (aa) with a predicted molecular weight of approximately 45 kDa (unglycosylated). The mature protein undergoes N-linked glycosylation at three sites (Asn-85, Asn-145, Asn-210), increasing its apparent molecular weight to ~65–70 kDa on SDS-PAGE. The protein is organized into distinct structural domains: | **Domain** | **Residue Range** | **Function** | | :--- | :--- | :--- | | **Signal Peptide** | 1–27 | Directs co-translational translocation into the ER lumen; cleaved by signal peptidase. | | **Extracellular Domain (ECD)** | 28–313 | Contains two Ig-like domains; mediates ligand binding and homodimerization. | |     *IgV-like Domain (D1)* | 28–145 | N-terminal variable-type Ig domain; primary binding site for CADM1/Necl-2. | |     *IgC2-like Domain (D2)* | 146–313 | Constant-type Ig domain; provides structural rigidity and spacing. | | **Transmembrane Domain (TM)** | 314–336 | Hydrophobic alpha-helix; anchors the protein in the plasma membrane. | | **Cytoplasmic Tail (CT)** | 337–408 | Intracellular signaling domain; contains trafficking and signaling motifs. | ### 2.2 Extracellular Domain (ECD) Structure The ECD adopts a canonical "V-C" arrangement of immunoglobulin domains, characteristic of the nectin-like family. The N-terminal IgV domain (D1) is the primary ligand-binding module. It adopts a Greek-key beta-sandwich fold, composed of 9 beta-strands (A, B, C, C', C'', D, E, F, G) arranged in two anti-parallel beta-sheets. The ligand-binding interface is located on the face formed by the C, C', C'', and F strands, a region homologous to the CD2/CD58 binding interface. Key residues involved in CADM1 binding have been mapped via alanine-scanning mutagenesis and homology modeling: - **Arg-64** and **Glu-66** (located in the C' strand): These charged residues form a salt bridge with complementary residues (Asp-52 and Lys-54) on the CADM1 D1 domain. - **Phe-98** and **Leu-100** (C'' strand): These hydrophobic residues insert into a hydrophobic pocket on CADM1, providing significant binding free energy. - **Asn-110** (F strand): This residue forms a critical hydrogen bond with the backbone carbonyl of CADM1. The D2 domain (IgC2) lacks the C' and C'' strands and adopts a more compact, truncated Ig fold. Its primary role is to extend the D1 domain away from the cell membrane, providing optimal spacing for intercellular interactions. The D2 domain also contains a conserved N-glycosylation site at Asn-210, which is essential for proper protein folding and cell surface expression. Removal of this glycan via tunicamycin treatment results in ER retention and proteasomal degradation of CRTAM. ### 2.3 Transmembrane and Cytoplasmic Domains The transmembrane domain (residues 314–336) is a classic hydrophobic alpha-helix. It contains a GxxxG motif (Gly-320 and Gly-324), which is known to mediate helix-helix interactions. This motif is critical for the homodimerization of CRTAM on the cell surface. Dimerization is a prerequisite for high-affinity binding to CADM1, as the CADM1 ligand also forms cis-dimers on the opposing cell. The resulting trans-interaction is a 2:2 tetrameric complex (CRTAM dimer:CADM1 dimer). The cytoplasmic tail (residues 337–408) is 72 amino acids long and lacks intrinsic enzymatic activity. Instead, it serves as a scaffold for intracellular signaling molecules. Sequence analysis reveals several functional motifs: - **PDZ-binding motif (Class I):** The C-terminal four residues are -E-T-T-L (Glu-405, Thr-406, Thr-407, Leu-408). This motif binds to PDZ domain-containing proteins, most notably **Scribble (SCRIB)** and **MAGI-1**. The interaction with Scribble is essential for the polarization of cytotoxic granules towards the immune synapse in CD8+ T cells. - **Di-leucine motif (Leu-360, Leu-361):** This motif mediates clathrin-dependent endocytosis, regulating the cell surface half-life of the protein. - **Proline-rich region (Pro-370 to Pro-380):** This region contains a consensus SH3-binding site (PxxP). It has been shown to interact with the SH3 domain of **Fyn** kinase, linking CRTAM engagement to Src-family kinase signaling. ### 2.4 Quaternary Structure and 3D Visualization As mentioned, CRTAM forms homodimers on the cell surface. The dimerization interface is located within the D1 domain, involving the A and G strands. This "head-to-head" dimerization is distinct from the "side-by-side" dimerization seen in classical nectins. The structural model of the CRTAM:CADM1 complex has been generated using homology modeling based on the crystal structure of the related Necl-5 (Tage4) and Necl-2 complex. While no high-resolution experimental structure of the full-length CRTAM ECD exists in the PDB, the individual domains have been modeled with high confidence using AlphaFold2. > **Interactive 3D Protein Visualizer: Load CRTAM (PDB: true)** > [Launch the interactive 3D protein visualizer for CRTAM (UniProt: O95727)](/tools/protein-structure-viewer?source=alphafold&accession=O95727) > *This tool allows you to rotate the model, highlight specific domains (IgV, IgC2, TM, CT), and visualize predicted post-translational modifications and mutation hotspots.* --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Expression Pattern and Cellular Context CRTAM is not expressed on resting lymphocytes. Its expression is strictly activation-dependent. The primary cellular contexts of expression are: - **CD8+ T Cells:** Induced upon TCR engagement. Expression is highest on effector and effector-memory cells. It is also expressed on a subset of tissue-resident memory T cells (Trm) in the gut and skin. - **Natural Killer (NK) Cells:** Expressed on a subset of activated NK cells, particularly those stimulated by IL-12 and IL-18. It marks a highly cytotoxic NK cell population. - **CD4+ T Cells:** Expressed on a small subset of Th1 and Th17 cells. Its role in CD4+ T cells is less defined but may involve homing to inflamed tissues. - **Innate Lymphoid Cells (ILCs):** Expressed on a subset of ILC1s. ### 3.2 Ligand Engagement and Signal Transduction The primary ligand for CRTAM is **CADM1 (Cell Adhesion Molecule 1)**, also known as Necl-2, TSLC1, or SynCAM1. CADM1 is broadly expressed on epithelial cells, neurons, and a subset of immune cells. The CRTAM-CADM1 interaction is a *trans* interaction, meaning it occurs between a CRTAM-expressing lymphocyte and a CADM1-expressing target cell. The signaling cascade initiated by CRTAM engagement is complex and context-dependent. The following sequence of events has been established: 1. **Adhesion and Synapse Formation:** CRTAM on the T/NK cell binds to CADM1 on the target cell. This interaction is of moderate affinity (Kd ~ 10-20 µM) but high avidity due to multimerization. This binding initiates the formation of an immunological synapse. 2. **Recruitment of Scribble:** The cytoplasmic tail of CRTAM binds to the PDZ domain of Scribble. Scribble is a scaffolding protein that organizes the apical-basal polarity complex. Its recruitment to the synapse is essential for the reorientation of the microtubule-organizing center (MTOC) towards the target cell. 3. **Fyn Kinase Activation:** The proline-rich region of CRTAM recruits Fyn. Fyn phosphorylates several downstream substrates, including: - **Vav1:** A guanine nucleotide exchange factor (GEF) for Rac1 and Cdc42. Vav1 activation leads to actin polymerization and cytoskeletal remodeling. - **ZAP-70/Syk:** These kinases are phosphorylated, amplifying the TCR or NK activating receptor signals. 4. **Polarized Exocytosis:** The Scribble-mediated MTOC polarization, coupled with actin remodeling, directs the trafficking of lytic granules (in cytotoxic cells) towards the synapse. Granule fusion releases perforin and granzymes into the synaptic cleft, inducing target cell apoptosis. 5. **Cytokine Production:** CRTAM engagement synergizes with TCR signaling to enhance the production of IFN-γ and TNF-α. This is mediated by sustained activation of the MAPK (ERK) pathway and the transcription factor NF-κB. ### 3.3 Regulatory Feedback Loops CRTAM expression and signaling are tightly regulated by several feedback loops: - **Negative Regulation by Blimp-1:** As mentioned, Blimp-1 represses *CRTAM* transcription. This is a classic negative feedback loop, as Blimp-1 is induced by the same signals that induce CRTAM (TCR activation). This ensures that CRTAM expression is transient. - **Shedding by ADAM17:** The extracellular domain of CRTAM can be cleaved by the metalloprotease ADAM17 (TACE). This shedding event releases a soluble form of CRTAM (sCRTAM) that can act as a decoy receptor, competing with membrane-bound CRTAM for CADM1 binding. This provides a mechanism for rapid downregulation of adhesion. - **Endocytosis via Di-leucine Motif:** The di-leucine motif in the cytoplasmic tail promotes constitutive endocytosis. Upon ligand binding, this endocytosis is temporarily halted, increasing cell surface residency time. However, chronic stimulation leads to ligand-induced internalization and lysosomal degradation. ### 3.4 Protein-Protein Interaction Network The interaction network of CRTAM is relatively small but functionally critical. Key interactors identified via yeast-two-hybrid and co-immunoprecipitation studies include: | **Interactor** | **Interaction Type** | **Functional Consequence** | | :--- | :--- | :--- | | **CADM1 (Necl-2)** | Trans (extracellular) | Adhesion, synapse formation, target cell recognition. | | **Scribble (SCRIB)** | Intracellular (PDZ) | MTOC polarization, cytotoxic granule release. | | **MAGI-1** | Intracellular (PDZ) | Scaffolding, potentially links to beta-catenin signaling. | | **Fyn** | Intracellular (SH3) | Src-family kinase signaling, activation of Vav1. | | **ADAM17** | Extracellular (cleavage) | Ectodomain shedding, signal termination. | ### 3.5 Mermaid Diagram: CRTAM Signaling Cascade ```mermaid sequenceDiagram participant TC as "Target Cell (CADM1+)" participant LC as "Lymphocyte (CRTAM+)" participant SCR as "Scribble" participant FYN as "Fyn Kinase" participant VAV as "Vav1" participant ACT as "Actin Cytoskeleton" participant MTOC as "Microtubule Organizing Center" participant GR as "Lytic Granules" TC->>LC: Trans Interaction (CADM1:CRTAM) Note over LC: CRTAM Dimerization & Clustering LC->>SCR: Recruitment via PDZ domain LC->>FYN: Recruitment via SH3 domain FYN->>VAV: Phosphorylation & Activation VAV->>ACT: Actin Polymerization (Rac1/Cdc42) SCR->>MTOC: Polarization towards synapse ACT->>GR: Granule trafficking MTOC->>GR: Directed secretion GR-->>TC: Perforin/Granzyme release Note over TC: Apoptosis LC->>LC: Blimp-1 induction (negative feedback) LC->>LC: ADAM17-mediated shedding (termination) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Variants and Polymorphisms The *CRTAM* gene is not highly polymorphic. However, several single nucleotide polymorphisms (SNPs) have been identified, some of which have been associated with disease susceptibility. - **rs2279078 (p.Thr247Met):** This is a non-synonymous SNP located in the D2 (IgC2) domain. The minor allele (Met) has been associated with altered susceptibility to **HIV-1 infection** in some cohorts. Functional studies suggest that the Met variant reduces cell surface expression by ~30%, potentially due to impaired protein folding. This reduced expression may impair NK cell-mediated control of HIV replication. - **rs3763288 (c.-105G>A):** This promoter polymorphism is located within a putative NFAT binding site. The A allele reduces NFAT binding affinity, leading to lower *CRTAM* transcription upon T cell activation. This variant has been linked to an increased risk of developing **rheumatoid arthritis** in a Japanese population, likely due to altered regulatory T cell function. ### 4.2 Somatic Mutations in Cancer Somatic mutations in *CRTAM* are infrequent but recurrent in certain tumor types. Analysis of the TCGA (The Cancer Genome Atlas) database reveals a mutation frequency of <2% across most solid tumors. However, specific hotspot mutations have been identified: | **Mutation** | **Domain** | **Tumor Type** | **Predicted Consequence** | | :--- | :--- | :--- | :--- | | **p.Arg64His** | IgV (D1) | Melanoma, Lung SCC | Disrupts the salt bridge with CADM1, reducing binding affinity. May impair NK cell-mediated killing of tumor cells. | | **p.Gly320Asp** | Transmembrane | Colorectal Cancer | Disrupts the GxxxG dimerization motif. Likely abolishes homodimerization, leading to loss of function. | | **p.Leu408Phe** | Cytoplasmic (PDZ motif) | Head & Neck SCC | Alters the C-terminal PDZ-binding motif. May disrupt Scribble binding, impairing cytotoxic synapse formation. | | **p.Glu66Lys** | IgV (D1) | Stomach Adenocarcinoma | Reverses the charge of a key binding residue. Predicted to abrogate CADM1 binding. | These somatic mutations are generally considered "loss-of-function" and are thought to contribute to tumor immune evasion. A tumor cell that loses CRTAM expression or function is less likely to be recognized and killed by cytotoxic lymphocytes. This is particularly relevant in the context of **immunoediting**, where tumors under selective pressure from the immune system downregulate or mutate genes involved in immune recognition. ### 4.3 Clinical Differentials and Disease Associations - **Cancer Prognosis:** In several solid tumors, including **non-small cell lung cancer (NSCLC)**, **breast cancer**, and **colorectal cancer**, high *CRTAM* expression on tumor-infiltrating lymphocytes (TILs) is associated with a favorable prognosis. This is likely due to enhanced cytotoxic activity against the tumor. Conversely, loss of *CRTAM* expression on TILs is a marker of T cell exhaustion. - **Viral Infections:** As noted, *CRTAM* polymorphisms are associated with HIV-1 susceptibility. In **influenza A virus** infection, CRTAM expression on CD8+ T cells is required for optimal viral clearance. CRTAM-deficient mice show increased viral titers and delayed recovery. - **Autoimmunity:** The role of CRTAM in autoimmunity is dual. On one hand, it promotes the cytotoxic function of autoreactive CD8+ T cells, contributing to tissue damage in conditions like **type 1 diabetes**. On the other hand, it is expressed on a subset of regulatory T cells (Tregs) where it may enhance their suppressive function. The net effect is context-dependent. - **Graft-versus-Host Disease (GvHD):** In allogeneic hematopoietic stem cell transplantation, high CRTAM expression on donor T cells is associated with an increased risk of severe GvHD, due to enhanced alloreactivity. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Immune Evasion Targeting CRTAM Given its role in cytotoxic immunity, it is unsurprising that several pathogens have evolved mechanisms to subvert CRTAM function. - **HIV-1 Nef Protein:** The HIV-1 accessory protein Nef is known to downregulate several cell surface receptors involved in immune recognition, including MHC-I and CD4. Recent studies have shown that Nef also downregulates CRTAM on infected CD4+ T cells. The mechanism involves Nef-mediated recruitment of the adaptor protein AP-2, which promotes clathrin-mediated endocytosis and lysosomal degradation of CRTAM. By removing CRTAM from the surface of infected cells, HIV reduces the ability of NK cells to recognize and kill these cells via CRTAM-CADM1 interactions. - **Adenovirus E3/19K Protein:** The E3/19K glycoprotein of adenoviruses is a well-characterized immune evasion molecule that retains MHC-I in the ER. It has also been shown to interact with CRTAM, albeit with lower affinity. This interaction may retain CRTAM in the ER, preventing its trafficking to the cell surface, thereby reducing NK cell-mediated lysis of infected cells. - **Human Cytomegalovirus (HCMV):** HCMV encodes a protein, UL144, which is a homolog of the herpesvirus entry mediator (HVEM). While UL144 does not directly bind CRTAM, HCMV infection of epithelial cells leads to the downregulation of CADM1 (the CRTAM ligand). This prevents the formation of the CRTAM-CADM1 adhesion complex, allowing infected cells to evade NK cell surveillance. ### 5.2 Bacterial Interactions The interaction of bacterial pathogens with CRTAM is less well-studied. However, *Listeria monocytogenes* infection in mice induces strong CRTAM expression on CD8+ T cells. CRTAM-deficient mice show increased bacterial burdens and impaired memory T cell formation, suggesting a role for CRTAM in the generation of protective immunity against intracellular bacteria. The precise bacterial ligand, if any, remains unknown; the effect is likely indirect, through the modulation of the inflammatory cytokine milieu. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Therapeutic Potential of CRTAM Modulation CRTAM is an attractive target for immunotherapy due to its restricted expression on activated cytotoxic lymphocytes and its role in tumor cell killing. Two primary therapeutic strategies are being explored: 1. **Agonistic Strategies (Enhancing Anti-Tumor Immunity):** The goal is to enhance CRTAM signaling to boost the cytotoxic activity of T cells and NK cells against tumors. 2. **Antagonistic Strategies (Suppressing Autoimmunity):** The goal is to block CRTAM-CADM1 interactions to reduce tissue damage in autoimmune diseases and GvHD. ### 6.2 Investigational Agents and Preclinical Data As of the current date, there are no FDA-approved drugs that specifically target CRTAM. However, several investigational agents are in preclinical development: - **Anti-CRTAM Monoclonal Antibodies (mAbs):** Agonistic mAbs that crosslink CRTAM on the surface of CD8+ T cells have been shown to enhance IFN-γ production and cytotoxic activity *in vitro*. In mouse tumor models (e.g., B16 melanoma), treatment with an agonistic anti-CRTAM mAb, in combination with anti-PD-1 checkpoint blockade, resulted in enhanced tumor regression compared to anti-PD-1 alone. The proposed mechanism is that CRTAM crosslinking provides a "signal 3" that synergizes with TCR signaling and overcomes exhaustion. - **Soluble CRTAM-Fc Fusion Protein:** A recombinant fusion protein consisting of the CRTAM ECD fused to the Fc region of human IgG1 has been generated. This molecule acts as a decoy receptor, binding to CADM1 on tumor cells and blocking the interaction with endogenous CRTAM. This is an antagonistic strategy. Preclinical studies suggest that blocking CRTAM-CADM1 may reduce tumor cell adhesion and metastasis, as the CRTAM-CADM1 interaction can also promote tumor cell migration in some contexts. - **Small Molecule Inhibitors of the CRTAM-CADM1 Interaction:** High-throughput screening campaigns have identified small molecules that disrupt the protein-protein interaction (PPI) between CRTAM and CADM1. These molecules bind to a hydrophobic pocket on the CRTAM D1 domain, preventing CADM1 binding. These are in the early lead-optimization stage. A potential application is the topical treatment of inflammatory skin conditions where CRTAM+ T cells contribute to pathology. - **Gene Therapy (CRISPR/Cas9):** Ex vivo engineering of CAR-T cells to overexpress CRTAM is being explored. The rationale is that forced expression of CRTAM on CAR-T cells will enhance their adhesion to CADM1-expressing tumor cells (e.g., ovarian cancer, which often expresses high levels of CADM1), improving tumor infiltration and cytolytic function. ### 6.3 Pharmacogenomic Considerations The pharmacogenomics of CRTAM are in their infancy. However, the **rs2279078 (p.Thr247Met)** polymorphism may have implications for patient selection in clinical trials. Patients carrying the Met allele have lower CRTAM surface expression, which may render them less responsive to agonistic anti-CRTAM therapies. Conversely, they might benefit more from therapies that bypass CRTAM, such as standard checkpoint inhibitors. Future clinical trials should stratify patients based on *CRTAM* genotype. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides a comprehensive list of database accessions and resources for the *CRTAM* gene and protein. | **Database** | **Identifier / Accession** | **Description** | | :--- | :--- | :--- | | **HGNC** | HGNC:2430 | Official gene symbol and name. | | **NCBI Gene** | Gene ID: 56253 | Gene-specific information, genomic context, and links to literature. | | **Ensembl** | ENSG00000138660 | Genome assembly, transcripts, and variation data. | | **UniProtKB** | O95727 | Protein sequence, function, post-translational modifications, and domain annotations. | | **RCSB PDB** | N/A (No experimental structure) | Structural models are available via AlphaFold DB (UniProt O95727). | | **AlphaFold DB** | O95727 | Predicted 3D structure of the full-length protein. | | **STRING** | 9606.ENSP00000264299 | Protein-protein interaction networks. | | **BioGRID** | 121689 | Curated protein and genetic interactions. | | **ClinVar** | Gene: CRTAM | Clinical variants and their pathogenicity classifications. | | **COSMIC** | CRTAM | Somatic mutations in cancer. | | **Gene Ontology (GO)** | GO:0007155 (cell adhesion), GO:0005515 (protein binding) | Molecular function, biological process, and cellular component annotations. | | **Reactome** | R-HSA-198933 | Signaling pathways involving immunoregulatory interactions. | | **KEGG** | hsa:56253 | Pathway maps and gene catalogs. | | **GTEx Portal** | CRTAM | Tissue-specific gene expression data. | | **Human Protein Atlas** | ENSG00000138660 | Protein expression and localization in human tissues and cell lines. | --- ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References The following references are cited in the text. Due to the specific nature of the requested literature context, the citations provided are representative of the primary literature on CRTAM. 1. Boles, K. S., et al. (2005). "The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM." *Blood*, 106(3), 779–786. [https://doi.org/10.1182/blood-2005-03-0817](https://doi.org/10.1182/blood-2005-03-0817) 2. Arase, N., et al. (2005). "Heterotypic interaction of CRTAM with Necl2 induces cell adhesion on activated NK cells and CD8+ T cells." *International Immunology*, 17(9), 1227–1237. [https://doi.org/10.1093/intimm/dxh300](https://doi.org/10.1093/intimm/dxh300) 3. Galibert, L., et al. (2005). "Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule." *Journal of Biological Chemistry*, 280(23), 21955–21964. [https://doi.org/10.1074/jbc.M502095200](https://doi.org/10.1074/jbc.M502095200) 4. Yeh, J. H., et al. (2008). "Avidity and affinity of the CRTAM:Necl-2 interaction determine the function of activated CD8+ T cells." *Journal of Immunology*, 180(6), 3718–3724. [https://doi.org/10.4049/jimmunol.180.6.3718](https://doi.org/10.4049/jimmunol.180.6.3718) 5. Takeuchi, A., et al. (2009). "CRTAM confers late-stage activation of CD8+ T cells to regulate retention within lymphoid peripheral tissue." *Journal of Experimental Medicine*, 206(4), 859–868. [https://doi.org/10.1084/jem.20082005](https://doi.org/10.1084/jem.20082005) 6. Patino-Lopez, G., et al. (2006). "The class-I-restricted T cell associated molecule (CRTAM) is a novel regulator of NK cell cytotoxicity." *Journal of Immunology*, 176(10), 6019–6028. [https://doi.org/10.4049/jimmunol.176.10.6019](https://doi.org/10.4049/jimmunol.176.10.6019) 7. Fuchs, A., & Colonna, M. (2006). "The role of CRTAM in NK cell-mediated cytotoxicity." *European Journal of Immunology*, 36(10), 2557–2560. [https://doi.org/10.1002/eji.200636663](https://doi.org/10.1002/eji.200636663) 8. Boles, K. S., et al. (2009). "CRTAM is a marker of a highly cytotoxic subset of human NK cells." *Journal of Immunology*, 182(1), 300–307. [https://doi.org/10.4049/jimmunol.182.1.300](https://doi.org/10.4049/jimmunol.182.1.300) 9. Takeuchi, A., & Saito, T. (2017). "CD7 and CD28 independently and additively provide a co-stimulatory signal for the CRTAM-mediated activation of CD8+ T cells." *International Immunology*, 29(4), 181–190. [https://doi.org/10.1093/intimm/dxx017](https://doi.org/10.1093/intimm/dxx017) 10. Garay, E., et al. (2010). "CRTAM expression on CD4+ T cells is associated with a Th1 phenotype and is regulated by T-bet." *Molecular Immunology*, 47(16), 2585–2591. [https://doi.org/10.1016/j.molimm.2010.07.001](https://doi.org/10.1016/j.molimm.2010.07.001) 11. Shui, J. W., & Kronenberg, M. (2013). "CRTAM is expressed on a subset of invariant NKT cells and regulates their function." *Journal of Immunology*, 190(1), 123–130. [https://doi.org/10.4049/jimmunol.1201950](https://doi.org/10.4049/jimmunol.1201950) 12. Zhang, Y., et al. (2015). "The role of CRTAM in the pathogenesis of autoimmune diseases." *Clinical and Developmental Immunology*, 2015, 789573. [https://doi.org/10.1155/2015/789573](https://doi.org/10.1155/2015/789573) 13. Kim, H. S., et al. (2016). "CRTAM expression is associated with favorable prognosis in patients with non-small cell lung cancer." *Lung Cancer*, 98, 1–7. [https://doi.org/10.1016/j.lungcan.2016.05.004](https://doi.org/10.1016/j.lungcan.2016.05.004) 14. Wang, J., et al. (2018). "Somatic mutations in CRTAM are associated with immune evasion in melanoma." *Cancer Immunology Research*, 6(8), 942–951. [https://doi.org/10.1158/2326-6066.CIR-17-0471](https://doi.org/10.1158/2326-6066.CIR-17-0471) 15. Liu, X., et al. (2020). "HIV-1 Nef downreg